Replies to post #180048 on Anavex Life Sciences Corp (AVXL)

[poguemahone]

Plexrec:

If what you say is true (about the lack of information regarding AVXL at 6 of 9 trial sites), that is somewhat of a concern.

Perhaps senior management needs to spend more time on getting the nuts and bolts of these trial sights up and running, and less time on preferred shares.

Since the most recent December conference call, what is Missling going to mention on this upcoming conference call that he has accomplished in the past 8 weeks? We've added a new member to our team, Dr. Kaufmann. That was a noteworthy addition, but it has been quiet since.

Will he provide an update on trial enrollments? I thought TGD was looking forward to sharing news on the status of these "imminently" (his words--not mine). What is his definition of imminently? Mine is within a month or two, but I guess he has a longer time horizon.

I sometimes wonder what the priorities of this company are.

[XenaLives]

What you are missing is it's the communication with the referring physicians that is most important.

And when they talk about the trial they may provide links to the larger sites.

[F1ash]

Alzheimer’s trials are very expensive and historically fail ~100% of the time. Why rush?

See if PDD shows promise first, especially since that trial is administering a lower dose. Probably no coincidence that dosages are hidden for the Alzheimer’s trial imho.

[jimmy667]

Simple explanation is an economically and logistically conservative action by the fact that intake and pre-test baselines will be more involved in the uptake of participants/patients. So centralize this front end heavy at three sites for the uptake and then complete all follow ups at all nine sites.